AVITA Medical to manufacture PermeaDerm; revenue share rises to 60%

AVITA Medical, Inc.

10-year contract manufacturing agreement for PermeaDerm at AVITA's Ventura, CA facility.
Revenue share for AVITA increases to 60% after manufacturing costs (was 50/50).
Stedical eligible for milestone payments tied to AVITA's achievement of sales targets.
Exclusive distribution agreement term extended to ten years from March 17, 2025.
PermeaDerm is FDA-cleared biosynthetic wound matrix; eligible for U.S. reimbursement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.